Antibody Tests for Neurologic Diseases

Number: 0340

Policy
Applicable CPT / HCPCS / ICD-10 Codes
Background
References

Policy

Scope of Policy

This Clinical Policy Bulletin addresses antibody tests for neurologic diseases.

Medical Necessity
1. Aetna considers antibody tests medically necessary for the diagnosis and treatment of paraneoplastic neurologic disorders when all of the following are met:
  1. The member displays clinical features of the paraneoplastic neurologic disease in question, and
  2. The result of the test will directly impact the treatment being delivered to the member, and
  3. After history, physical examination, and completion of conventional diagnostic studies, a definitive diagnosis remains uncertain, and one of the following antibodies is suspected:
    1. Anti-AChR
    2. Anti-amphiphysin
    3. Anti-bipolar cells of the retina
    4. Anti-CV2/CRMP5
    5. Anti-Hu (ANNA-1)
    6. Anti-KLHL11
    7. Anti-Ma (MA1, MA2) (Anti-Ta)
    8. Anti-recoverin
    9. Anti-Ri (ANNA-2)
    10. Anti-Tr
    11. Anti-VGCC
    12. Anti-VGKC
    13. Anti-Yo (APCA-1)
    14. Anti-nAChR.
2. Aetna considers antibody tests medically necessary for the diagnosis and treatment of neurologic diseases when all of the following are met:
  1. The member displays clinical features of the neurologic disease in question; and
  2. The result of the test will directly impact the treatment being delivered to the member; and
  3. After history, physical examination, and completion of conventional diagnostic studies, a definitive diagnosis remains uncertain, and one of the following antibodies is suspected:
    1. Anti-AChR
    2. Anti-asialo-GM1
    3. Anti-GM1
    4. Anti-GM2
    5. Anti-GAD
    6. Anti-GD1a
    7. Anti-GD1b
    8. Anti-GQ1b
    9. Anti-GT1a
    10. Anti-La
    11. Anti-MAG
    12. Anti-MUSK
    13. Anti-Ro
    14. Anti-SGPG
    15. Anti-sulfatide
    16. Anti-VGCC.
3. Aetna considers the LEMS antibody test to detect antibodies to the P/Q VGCC medically necessary in confirming the diagnosis of Lambert-Eaton myasthenic syndrome when the clinical features and electrophysiology studies are inconclusive in diagnosing Lambert-Eaton myasthenic syndrome.
4. Aetna considers RNA polymerase III antibody testing medically necessary for diagnosis and prognostication of scleroderma (systemic sclerosis).
5. Aetna considers serum MOG-IgG antibody testing medically necessary for evaluation of individuals with clinical presentations that should raise suspicion for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Clinical presentations that should raise suspicion for MOGAD include the following:
  - Optic neuritis that is simultaneously bilateral, involves the anterior optic pathway, and is associated with optic disc edema.
  - Acute disseminated encephalomyelitis (ADEM) or ADEM-like presentations accompanied by large, poorly demarcated T2 hyper-intense lesions in the brain and with T2 lesions within the spinal cord.
  - Unilateral cortical encephalitis with headache, fever, seizures, encephalopathy, or other focal neurologic findings with cortical T2 hyper-intensity and swelling.
  - A complete (rather than partial) spinal cord syndrome, especially with prominent bowel, bladder, or erectile dysfunction symptoms.
6. Aetna considers measurement of cerebrospinal fluid myelin oligodendrocyte glycoprotein antibodies medically necessary for diagnosing MOG-IgG-associated encephalomyelitis (MOG-EM).
7. Aetna considers measurement of serum folate receptor autoantibodies (e.g., FRAT (Folate Receptor Antibody Test)) medically necessary for evaluation of individuals with cerebral folate deficiency syndrome.
Experimental, Investigational, or Unproven

The following procedures are considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established:
1. Anti-HH3 and Ns6S antibody testing for the diagnosis/evaluation of amyotrophic lateral sclerosis (ALS)-motor neuron disease.
2. Antibody tests for screening of neurologic diseases. These tests are only considered medically necessary when ordered selectively for evaluating persons with signs and symptoms of specific immune-mediated neuromuscular conditions.
3. Auto-antibodies (Abs) (e.g., glycine receptor Abs (GlyR-Ab), myelin oligodendrocyte glycoprotein (MOG)-Ab, N-methyl-D-aspartate receptor (NMDAR)-Ab, and voltage-gated potassium channel (VGKC)-complex Abs) testing for the diagnosis of childhood-acquired demyelinating syndromes.
4. MOGAD antibody testing for persons with clinical and laboratory features that are typical for multiple sclerosis.
5. Routine anti-neuronal antibodies testing for early (less than 3 years of age) childhood-onset epilepsy without other features of autoimmune encephalitis.
Related Policies
- CPB 0285 - Plasmapheresis/Plasma Exchange/Therapeutic Apheresis
- CPB 0206 - Parenteral Immunoglobulins

Table:
CPT Codes / HCPCS Codes / ICD-10 Codes
Code	Code Description
CPT codes covered if selection criteria are met:
Measurement of CSF myelin oligodendrocyte glycoprotein antibodies - no specific code:
0399U	Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgGbinding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected
0432U	Kelch-like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method [NMO-IgG autoantibody test]
86041	Acetylcholine receptor (AChR); binding antibody
86042	blocking antibody
86043	modulating antibody
86362	Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each
86363	flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each
86366	Muscle-specific kinase (MuSK) antibody
CPT codes not covered for indications listed in the CPB (not all-inclusive):
Anti-HH3 and Ns6S antibody testing; anti-neuronal antibodies testing – No specific code
0431U	Glycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell-binding assay (LCBA), qualitative
Other CPT codes related to the CPB:
83519	Immunoassay, analyte, quantitative; by radiopharmaceutical technique (eg, RIA) [LEMS antibody test]
83520	not otherwise specified
84182	Protein, Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each
84238	Receptor assay; non-endocrine (specify receptor)
86235	Extractable nuclear antigen, antibody to, any method (e.g., nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody
86255	Fluorescent noninfectious agent antibody; screen, each antibody [LEMS antibody test]
ICD-10 codes covered if selection criteria are met:
E53.8	Deficiency of other specified B group vitamins [cerebral folate deficiency syndrome]
G04.81	Other encephalitis and encephalomyelitis [MOG-IgG-associated encephalomyelitis (MOG-EM)]
G13.0	Paraneoplastic neuromyopathy and neuropathy
G37.81	Myelin oligodendrocyte glycoprotein antibody disease
H46.9	Optic neuritis, unspecified
M34.0 – M34.9	Systemic sclerosis [scleroderma]
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
G12.21	Amyotrophic lateral sclerosis
G35	Multiple sclerosis
G36.0	Neuromyelitis optica [Devic]
G37.0	Diffuse sclerosis of central nervous system [Schilder's disease]
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G37.89 - G37.9	Other and unspecified demyelinating diseases of central nervous system
G40.001 - G40.B19	Epilepsy and recurrent seizures [early childhood-onset epilepsy]
G61.0	Guillain-Barre syndrome
G61.89	Other inflammatory polyneuropathies
G62.89	Other specified polyneuropathies
G64	Other disorders of peripheral nervous system
Z13.858	Encounter for screening for other nervous system disorders

Background

Autoantibodies to nervous system components have been detected in patients with neurologic symptoms such as paresthesia, weakness, and twitching. Many autoantibodies have been discovered and characterized; however, research is ongoing in the field of neuroimmunology and there remains a paucity of clinical trials in the peer-reviewed medical literature describing their usefulness in clinical practice. In a review on the use of autoantibodies as predictors of disease, Scofield (2004) stated that long-term large studies of outcome are needed to assess the use of assaying autoantibodies for prediction of disease. A review of laboratory testing in peripheral nerve disease indicated that the use of antibody assays should be very selective and should not be used as "screening" studies. Antibody testing often produces results that can be confusing; thus, a stepwise and directed approach to the evaluation of peripheral neuropathy utilizing clinical examination and electrodiagnostic testing can increase the yield of finding a treatable cause (Chang, 2002).

Antibodies to Glycolipid and Glycoprotein-Related Saccharides (MAG, GM1, Asialo-GM1 (Anti-GA1), GD1a, GD1b, GQ1b, MAG-SGPG, Sulfatide) (See Appendix for Complete List)

Gangliosides are a group of glycosphingolipids widely distributed in membrane components of the nervous system. They possess a common long chain fatty acid, but exhibit distinctive carbohydrate moieties containing one or more sialic acid residues. Ganglioside nomenclature is defined by the following scheme:

G refers to ganglio;
M, D, T, and Q refer to the number of sialic acid residues (mono, di, tri, and quad); and
numbers and lower case letters refer to the sequence of migration on thin layer chromatography.

The gangliosides most commonly recognized by neuropathy associated autoantibodies are GM1, asialo-GM1, GD1a, GD1b, and GQ1b.

Chronic immune-mediated polyneuropathies in which the peripheral nerves are selectively affected include chronic inflammatory demyelinating polyneuropathy (CIDP), demyelinating polyneuropathy associated with IgM anti-myelin-associated glycoprotein (anti-MAG)) antibodies or anti-sulfoglucuronyl paragloboside (anti-SGPG) antibodies, multi-focal motor neuropathy associated with IgM anti-ganglioside M1 (anti-GM1) or anti-GD1a antibodies, and sensory polyneuropathy associated with IgM anti-sulfatide antibodies or anti-GD1b or disialosyl ganglioside antibodies. Some of these autoantibodies also occur as IgM monoclonal gammopathies in patients with non-malignant monoclonal gammopathies.

Detection of ganglioside M1 (GM1) antibody, usually of the IgM isotype, is associated with multi-focal motor neuropathy and lower motor neuropathy, characterized by muscle weakness and atrophy. Multi-focal motor neuropathy may occur with or without high serum titers of anti-GM1 antibodies. GM1 antibodies are detected in approximately 50 % of persons with multi-focal motor neuropathy (Tidy, 2007). However, whether the presence of anti-GM1 antibody or its titer has any bearing on the response to therapy is controversial (Sridharan and Lorenzo, 2002).

GM1 antibodies of the IgG and IgA isotypes may be found in association with amyotrophic lateral sclerosis (ALS). European Federation of Neurological Societies (EFNS) guidelines (2006) on amyotrophic lateral sclerosis recommend testing for anti-GM1, as well as anti-MAG and anti-Hu antibodies (see below) in selected cases.

Ganglioside glycolipid antibodies may be associated with different forms or aspects of Guillain-Barre Syndrome (GBS). Increased titers of IgG anti-GM1 or GD1a ganglioside antibodies have been associated with GBS and acute motor axonal neuropathy, and may be useful in persons suspected of having these syndromes. Antibodies to GM1 and GD1a are mostly associated with axonal variants of GBS. Antibodies to GT1a are associated with swallowing dysfunction. The GD1b ganglioside is present in peripheral nerves on the surface of sensory neurons in the dorsal root ganglion. Antibodies to GD1b are associated with pure sensory GBS.

Increased IgG anti-GQ1b ganglioside antibodies are closely associated with the Miller-Fisher syndrome, and may be useful in the evaluation of patients suspected of having this syndrome. Antibodies against GQ1b are found in 85 to 90 % of patients with the Miller Fisher syndrome, characterized by ataxia, areflexia, and ophthalmoplegia. In clinical practice, commercially available testing for serum IgG antibodies to GQ1b is useful for the diagnosis of Miller Fischer syndrome, having a sensitivity of 85 to 90 %. GQ1b antibodies are also found in GBS patients with ophthalmoplegia, but not in GBS patients without ophthalmoplegia. Antibodies to GQ1b may also be present in Bickerstaff encephalitis and the pharyngo-cervical brachial GBS variant, but not in disorders other than GBS.

Myelin-associated glycoprotein (MAG) is a constituent of peripheral and central nervous system myelin. High titer IgM antibodies to MAG are associated with sensorimotor demyelinating peripheral neuropathy, and are associated with multiple sclerosis, myasthenia gravis, and systemic lupus erythematosus (SLE) (Tidy, 2007).

Antibodies recognizing MAG react with a carbohydrate determinant that is also present on SGPG. Initial assays for MAG antibody utilized SGPG as the target antigen. However, some laboratories now perform 2 separate enzyme-linked immunosorbant assay (ELISA) procedures, one utilizing SGPG as antigen and one utilizing the entire MAG as antigen, to maximize detection of MAG antibodies. Researchers are currently examining the cross-reacted relationship of IgM binding to both SGPG and MAG and their significance in neuropathy (Garces-Sanchez, 2008).

MAG antibodies are usually associated with the presence of an IgM monoclonal protein; approximately 50 % of patients with IgM monoclonal gammopathies and associated peripheral neuropathies have detectable MAG antibodies. Detection of MAG antibodies may be useful in paraprotein demyelinating neuropathies. EFNS guidelines (2006) state that a causal relationship between a paraprotein and a demyelinating neuropathy is highly probable if there is an immunoglobulin M (IgM) paraprotein (monoclonal gammopathy of uncertain significance [MGUS] or Waldenstrom's) and there are high titers of anti-MAG or anti-GQ1b antibodies. A causal relationship is probable in persons with IgM paraprotein (MGUS or Waldenström's) with high titers of IgM antibodies to other neural antigens (GM1, GD1a, GD1b, GM2, sulfatide), and slowly progressive predominantly distal symmetrical sensory neuropathy.

Guidelines from the British Society of Haematology recommend testing for anti-MAG in persons with Waldenstrom's macroglobulinemia who present with neurological symptoms (Johnson et al, 2005).

High titers of antibodies to the ganglioside asialo GM1 (anti-GA1) have been associated with motor or sensorimotor neuropathies. In most cases, these antibodies cross-react with the structurally related glycolipids GM1 and GD1b, although specific anti-asialo GM1 antibodies have also been reported (Lopez, 2006). Some individuals with proximal lower motor neuron syndromes (P-LMN) (30 %) have selective serum antibody binding to asialo-GM1 ganglioside; however, there is no evidence that P-LMN syndromes respond to immunosuppressive treatment.

Antibodies Associated with Paraneoplastic Syndromes and Associated Cancers (Anti-Hu, Anti-Yo, Anti-Ri, Anti-VGKC, Anti-VGCC, Anti-CV2, Anti-Ma, Anti-Amphiphysin, Anti-Zic4) (See Appendix for Complete List)

Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system from cerebral cortex to neuromuscular junction and muscle, either damaging one area or multiple areas. Although a pathogenic role of paraneoplastic antibodies has not been proven, their presence indicates the paraneoplastic nature of a neurologic disorder, and in many cases, can narrow the search for an occult tumor to a few organs.

Polyclonal immunoglobulin G (IgG) anti-Hu antibodies (previously called ANNA-1) are found predominantly in patients with paraneoplastic neurologic syndromes associated with small-cell carcinoma of the lung. Anti-Hu antibodies are also expressed in most neuroblastomas and occasional other tumors (including several types of sarcoma and prostate carcinoma). Anti-Hu antibody reacts with 35- to 42-kD proteins present in nuclei and cytoplasm of virtually all neurons. The role of Hu proteins in small-cell lung cancer and the other cancers in which they are expressed is unclear (Mehdi and Ko, 2002). Some investigators have argued that detection of anti-Hu antibody is important to determine whether a paraneoplastic syndrome is immune-mediated and thus, in theory, amenable to immunosuppressive therapy (Santacroce et al, 2002; Senties-Madrid and Vega-Boada, 2001). However, the value of immunosuppressive therapy in antibody associated paraneoplastic syndromes has not been proven in clinical studies. Although the titer of anti-Hu antibodies has been suggested as a prognostic indicator of paraneoplastic neurologic syndromes, the clinical course of these syndromes is unpredictable (Liebeskind, 2001).

Paraneoplastic limbic encephalitis (PLE) is a rare disorder characterized by personality changes, irritability, depression, seizures, memory loss and sometimes dementia. The diagnosis is difficult because clinical markers are often lacking and symptoms usually precede the diagnosis of cancer or mimic other complications. Limbic encephalitis may be associated with voltage-gated potassium channel antibodies (VGKC) (53 %). However, responsiveness to treatment is not limited to patients with VGKC antibodies (Bataller, 2007). Other paraneoplastic encephalomyelitis antibodies include anti-CV2, anti-Ma1, anti-Ma2 (anti-Ta, anti-MaTa), and several other atypical antibodies. The targets of such antibodies may be quite varied, including neuropil and intraneuronal sites. Testicular cancer is associated with anti-Ma2 antibodies. The Ma2 antigen is selectively expressed in neurons and the testicular tumor. Ma2 shares homology with Ma1, a gene that is associated with other paraneoplastic neurologic syndromes, particularly brainstem and cerebellar dysfunction. Treatment of the tumor is reported to have more effect on neurologic outcome than the use of immune modulation (Gultekin, 2000).

The diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) is usually made on clinical grounds and confirmed by electrodiagnostic studies. A serum test for voltage-gated calcium channel antibodies (VGCC) is commercially available. Treatment involves removing the cancer associated with the disease. If cancer is not found, immunosuppressive medications and acetylcholinesterase inhibitors are used with moderate success. Patients with idiopathic LEMS should be screened every 6 months with chest imaging for cancer (Mareska, 2004).

Anti-Yo antibodies (also called Purkinje cell antibody type 1 or PCA-1) primarily occur in patients with paraneoplastic cerebellar degeneration (PCD) who have breast cancer or tumors of the ovary, endometrium, and fallopian tube. The target antigens of anti-Yo antibodies are the cdr proteins that are expressed by Purkinje cells and ovarian and breast cancers. A cytotoxic T cell response against cdr2 has also been identified in these patients.

Anti-CV2 antibodies, directed against a cytoplasmic antigen in some glial cells, and against peripheral nerve antigens, have been associated with several syndromes, including cerebellar degeneration, limbic encephalitis, encephalomyelitis, peripheral neuropathy, and optic neuritis. The most common tumors are SCLC, thymoma, and uterine sarcoma.

Opsoclonus is a disorder of ocular motility characterized by spontaneous, arrhythmic, conjugate saccades occurring in all directions of gaze without a saccadic interval. Although opsoclonus can be paraneoplastic in origin, it can also result from viral infections, post-streptococcal pharyngitis, metabolic disorders, metastases, and intra-cranial hemorrhage. The most frequent tumor associated with opsoclonus myoclonus in adults is small cell lung cancer. In women, however, the detection of anti-Ri (anti-neuronal nuclear autoantibody type 2, or ANNA-2) usually indicates the presence of breast cancer, although other tumors have been reported (e.g., gynecologic, lung, bladder). The target antigens of anti-Ri antibodies are the Nova proteins.

In a cross-sectional study, Pranzatelli et al (2002) examined paraneoplastic antibodies in 59 children with opsoclonus-myoclonus-ataxia, 86 % of them were moderately or severely symptomatic, and 68 % of them had relapsed at the time of testing. This total number of patients includes 18 children with low-stage neuroblastoma (tested after tumor resection), 6 of them had never been treated with immunosuppressants. All were sero-negative for anti-Hu, anti-Ri (IgG autoantibody ANNA-2), and anti-Yo (antibodies against a Purkinje cell cytoplasmic antigen, called Yo), the 3 paraneoplastic antibodies most associated with opsoclonus-myoclonus or ataxia in adults. The findings of this study suggested that anti-Hu, anti-Ri, and anti-Yo do not explain relapses in pediatric opsoclonus-myoclonus-ataxia.

Paraneoplastic optic neuritis has been described in a few reports, usually in association with paraneoplastic encephalomyelitis or retinitis and small cell lung cancer. Some of these patients harbor antibodies to the 62kDa collapsin-responsive mediator protein-5 (CRMP-5, also called anti-CV2). However, the small number of patients, the extensive number of accompanying symptoms, and the frequent co-occurrence of other antibodies suggest low specificity and sensitivity of CRMP-5 antibodies as markers of paraneoplastic optic neuritis or retinitis associated with small cell lung cancer.

Anti-Ro/SSA and anti-La/SSB antibodies, which are directed against two extractable nuclear antigens, have been detected with high frequency in patients with Sjögren's syndrome. They also have diagnostic usefulness in patients with SLE. Indications for ordering an anti-Ro/SSA antibody test include: women with SLE who have become pregnant; women who have a history of giving birth to a child with heart block or myocarditis; patients with a history of unexplained photosensitive skin eruptions; patients suspected of having a systemic connective tissue disease in whom the screening ANA test is negative; patients with symptoms of xerostomia, keratoconjunctivitis sicca and/or salivary and lacrimal gland enlargement; and patients with unexplained small vessel vasculitis or atypical multiple sclerosis.

Retinal antibodies have been associated with small cell carcinoma of the lung (Tidy, 2007).

In patients with neurologic symptoms of unknown cause, detection of Zic4 antibodies has been associated with cerebellar degeneration and small-cell lung cancer (SCLC) and often associates with anti-Hu or CRMP5 antibodies (Bataller, 2004). However, there is insufficient evidence on the clinical usefulness of measuring Zic4 antibodies in the peer-reviewed medical literature.

Stiff-Person Syndrome

Stiff-person syndrome (formerly called stiff-man syndrome) is an uncommon disorder characterized by progressive muscle stiffness, rigidity, and spasm involving the axial muscles. The muscle spasms are triggered by different stimuli and may lead to limb deformities and fracture. Electrophysiological studies show continuous discharges of motor unit potentials, which improve during sleep or general anesthesia. Paraneoplastic stiff-person syndrome usually occurs in patients with breast cancer and small cell lung cancer (SCLC). Paraneoplastic muscle rigidity in association with myoclonus has also been described in patients with SCLC and progressive encephalomyelitis. The serum of patients with paraneoplastic stiff-person syndrome often contains antibodies against a protein called amphiphysin. In contrast, patients with stiff-person syndrome who do not have cancer (but who usually develop diabetes and other symptoms of endocrinopathy) have antibodies against glutamic acid decarboxylase (GAD). Both GAD and amphiphysin are nonintrinsic membrane proteins that are concentrated in nerve terminals, where a pool of both proteins is associated with the cytoplasmic surface of synaptic vesicles.

To better understand GADAb and SPS, Murinson et al (2004) studied a population of patients with clinically suspected SPS. A total of 576 patients with suspected SPS underwent ICC. Of these, 286 underwent RIA for GADAb; 116 were GADAb-positive by one or both tests. Ninety-six percent of those positive by ICC had RIA values several standard deviations above normal. RIA did not correlate with age or illness duration. Marked elevations of RIA for GADAb were characteristic of ICC-confirmed SPS, and modest elevations were not. The findings of this study indicated that patients with clinically suspected SPS almost always have either very high GADAb or undetectable GADAb. An additional important observation was that the specificity of RIA for GAD-positive SPS is sharply dependent on the diagnostic cut-off value. The authors noted that until a universal standard for GAD65 RIA is adopted, interpretation will depend on knowing the particularities of each testing laboratory.

In an editorial, Chang and Lang (2004) stated that "the data from the Murinson, et al. do not imply a pathogenic role because they found no correlation between age or duration of illness and GADAbs and no change over the course of the disease in individuals. Thus, there is no value in monitoring the antibody titer during the course of disease .... Although the exact role of GADAbs in the pathogenesis of SPS still remains elusive, Murinson, et al. have established the reliability of RIA in measuring these antibodies. Nevertheless, clinical criteria remain the benchmark for the diagnosis of SPS".

Myasthenia Gravis (MuSk, AChR Antibodies)

Myasthenia gravis (MG), an autoimmune disorder, is caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction. These proteins include the nicotinic acetylcholine receptors (AChRs) or, less frequently, a muscle-specific tyrosine kinase (MuSK) involved in AChRs clustering. Chan and Liu (2005) noted that diagnosis of MG relies on clinical as well as investigatory evidences. Among the usual investigatory tools, the Tensilon (edrophonium chloride) test has been given the credit as a test of high sensitivity (80 to 85 %). Antibodies to AChRs are found in about 80 % of persons with myasthenia gravis (Tidy, 2007).

Vincent and Leite (2005) noted that some of the 20 % of patients with MG who do not have antibodies to AChRs have antibodies to MuSK, but a full understanding of their frequency, the associated clinical phenotype and the mechanisms of action of the antibodies has not yet been achieved. Moreover, some patients do not respond well to conventional corticosteroid therapy. These researchers reported that MuSK antibodies are found in a variable proportion of AChR antibody negative MG patients who are often, but not exclusively, young adult females, with bulbar, neck, or respiratory muscle weakness. The thymus histology is normal or only very mildly abnormal. Surprisingly, limb or intercostal muscle biopsies exhibit no reduction in AChR numbers or complement deposition. However, patients without AChR or MuSK antibodies appear to be similar to those with AChR antibodies and may have low-affinity AChR antibodies. A variety of treatments, often intended to enable corticosteroid doses to be reduced, have been used in all types of MG with some success, but they have not been subjected to randomized clinical trials. The authors noted that MuSK antibodies define a form of MG that can be difficult to diagnose, can be life threatening and may require additional treatments. An improved AChR antibody assay may be helpful in patients without AChR or MuSK antibodies. Randomized clinical studies of drugs in other neuroimmunological diseases may help to guide the treatment of MG.

Romi et al (2005) examined MG severity and long-term prognosis in seronegative MG compared with seropositive MG, and reviewed specifically at anti-AChR antibody negative and anti-MuSK antibody negative patients. A total of 17 consecutive sero-negative non-thymomatous MG patients and 34 age- and sex-matched contemporary sero-positive non-thymomatous MG controls were included in a retrospective follow-up study for a total period of 40 years. Clinical criteria were assessed each year, and muscle antibodies were assayed. There was no difference in MG severity between sero-negative and sero-positive MG. However, when thymectomized patients were excluded from the study at the year of thymectomy, sero-positive MG patients had more severe course than sero-negative (p < 0.001). One sero-positive patient died from MG related respiratory insufficiency. The need for thymectomy in sero-negative MG was lower than in sero-positive MG. None of the sero-negative patients had MuSK antibodies. The findings of this study showed that the presence of AChR antibodies in MG patients correlates with a more severe MG. The authors noted that with proper treatment, especially early thymectomy for seropositive MG, the outcome and long-term prognosis is good in patients with and without AChR antibodies.

Lee et al (2006) stated that several reports from Western countries suggest differences in the clinical features of patients with MuSK antibody-positive and MuSK antibody-negative sero-negative MG. These investigators performed the first survey in Korea of MuSK antibodies, studying 23 patients with AChR-antibody sero-negative MG. MuSK antibodies were present in 4 (26.7 %) of 15 generalized sero-negative MG patients and none of 8 ocular sero-negative MG patients. All 4 MuSK positive patients were females, with pharyngeal and respiratory muscle weakness, and required immunosuppressive treatment. However, overall disease severity and age at onset was similar to that of MuSK-negative MG and treatment responses were equally good.

In the appropriate clinical setting (lack of AChR-Ab and typical clinical features listed below), MuSK testing can clarify the diagnosis and perhaps direct treatment. However, the initial management of clinically apparent myasthenia should be the same for patients with or without AChR antibodies; this would change only if future studies find additional therapeutic differences related to MuSK status.

Although some differences between MuSK-positive and MuSK-negative MG have been found, the initial management of clinically apparent MG should be the same for patients with or without MuSK antibodies; this would change only if future studies show significant therapeutic differences related to MuSK status.

GALOP Autoantibody

A peripheral neuropathy syndrome described by Pestronk (1994) is the gait disorder, autoantibody, late-age onset, polyneuropathy (GALOP) syndrome that resembles anti-MAG neuropathies with distal sensory loss, ataxia, and demyelinating features on nerve conduction velosity testing. High titer IgM antibodies bind to a central nervous system myelin antigen preparation that copurifies with MAG. GALOP syndrome appears to be immune-mediated. However, there is insufficient evidence on the clinical usefulness of measuring the GALOP autoantibody for the diagnosis and treatment of GALOP syndrome in the peer-reviewed medical literature.

Finally, it has been estimated that up to 1/3 of peripheral neuropathies are idiopathic. These neuropathies are classified by their clinical syndrome, which include sensory axonal polyneuropathy with large and small fiber involvement, small-fiber sensory neuropathy, large-fiber sensory neuropathy, sensorimotor neuropathy, and autonomic neuropathy (Shy-Drager syndrome). Treatment is usually symptomatic, although some patients may respond to a trial of immunotherapy. More research into their causes as well as the development of better diagnostic tests and treatments are needed (Chang, 2002).

Dermatomyositis/Polymyositis

Several serological abnormalities (e.g., formation of specific autoantibodies) have been identified in patients with dermatomyositis (DM) and polymyositis (PM), however their routine use has not yet been established. As a group, these antibodies have been termed myositis-specific antibodies (MSAs) and include antibodies to EJ, Jo-1, Ku, Mi-2, OJ, PL-7, PL-12, signal recognition protein (SRP), and U2 small nuclear ribonucleoprotein (snRNP). Pappu and Seetharaman (2009) stated that anti-nuclear antibody assay findings are positive in 1/3 of patients with PM and in only 15 % of patients with inclusion body myositis, and about 4 % of patients with PM have antibodies to SRPs. Miller (2009) noted that electromyography (EMG) and tissue biopsies of skin and/or muscle are important facets of the evaluation of patients with possible DM or PM. Abnormalities in EMG may support the diagnosis of DM or PM but are not diagnostic. Moreover, skin biopsy (e.g., findings of Gottron's sign, the shawl sign, and erythroderma) can provide confirmation of the diagnosis of DM. In addition, muscle biopsy is the definitive test for PM, in which skin lesions are not seen.

Although MSA may offer valuable information regarding prognosis and potential future patterns of organ involvement, there is no reliable evidence that detection of these antibodies influences clinical management. Furthermore, while there is some limited evidence on the association between the presence of MSA with cancer-associated myositis (CAM), the available literature on this association is limited. Chinoy et al (2007) stated that these antibody tests are not foolproof, and do not replace the need for intensive surveillance for cancer in persons with new onset myositis. The authors concluded that before these results can be applied clinically, confirmation in a large independent trial with prospective follow-up is needed.

Kalluri et al (2009) stated that the anti-synthetase syndrome consists of interstitial lung disease (ILD), arthritis, myositis, fever, mechanic's hands, and Raynaud phenomenon in the presence of an anti-synthetase autoantibody, most commonly anti-Jo-1. It is believed that all the anti-synthetases are associated with a similar clinical profile, but definitive data in this diverse group are lacking. These researchers examined the clinical profile of anti-PL-12, an anti-synthetase autoantibody directed against alanyl-transfer RNA synthetase. A total of 31 subjects with anti-PL-12 autoantibody were identified from the databases at the Medical University of South Carolina, the University of Pittsburgh Medical Center, Johns Hopkins Medical Center, and Brigham and Women's Hospital. The medical charts were reviewed and the following data were recorded: demographic information; pulmonary and rheumatological symptoms; connective tissue disease (CTD) diagnoses; serological autoantibody findings; CT scan results; BAL findings; pulmonary function test results; lung histopathology; and treatment interventions. The median age at symptom onset was 51 years; 81 % were women and 52 % were African American; 90 % of anti-PL-12-positive patients had ILD, 65 % of whom presented initially to a pulmonologist; 90 % of anti-PL-12-positive patients had an underlying CTD. Polymyositis and DM were the most common underlying diagnoses. Raynaud phenomenon occurred in 65 % of patients, fever in 45 % of patients, and mechanic's hands in 16 % of patients. Test results for the presence of antinuclear antibody were positive in 48 % of cases. The authors concluded that anti-PL-12 is strongly associated with the presence of ILD, but less so with myositis and arthritis.

Derfuss and Meinl (2012) stated that identification of auto-antigens in demyelinating diseases is essential for the understanding of the pathogenesis. Immune responses against these antigens could be used as biomarkers for diagnosis, prognosis and treatment responses. Knowledge of antigen-specific immune responses in individual patients is also a prerequisite for antigen-based therapies. A proportion of patients with demyelinating disease have antibodies to aquaporin 4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG). Patients with anti-AQP4 have the distinct clinical presentation of neuromyelitis optica (NMO), and these patients often also harbor other autoimmune responses. In contrast, anti-MOG is seen in patients with different disease entities such as childhood multiple sclerosis (MS), acute demyelinating encephalomyelitis (ADEM), anti-AQP4 negative NMO, and optic neuritis, but hardly in adult MS. A number of new candidate auto-antigens have been identified and await validation. Antigen-based therapies are mainly aimed at tolerizing T-cell responses against myelin basic protein (MBP) and have shown only modest or no clinical benefit so far. The authors concluded that currently, only few patients with demyelinating diseases can be characterized based on their auto-antibody profile. The most prominent antigens in this respect are MOG and AQP4. Moreover, they stated that further research has to focus on the validation of newly discovered antigens as biomarkers.

Reindl et al (2013) noted that MOG has been identified as a target of demyelinating auto-antibodies in animal models of inflammatory demyelinating diseases of the central nervous system (CNS), such as MS. Numerous studies have aimed to establish a role for MOG antibodies in patients with MS, although the results have been controversial. Cell-based immunoassays using MOG expressed in mammalian cells have demonstrated the presence of high-titer MOG antibodies in pediatric patients with ADEM, MS, AQP4-seronegative NMO, or isolated optic neuritis (ON) or transverse myelitis (TM), but only rarely in adults with these disorders. These studies indicated that MOG antibodies could be associated with a broad spectrum of acquired human CNS demyelinating diseases. The authors discussed the current literature on MOG antibodies, their potential clinical relevance, and their role in the pathogenesis of MOG antibody-associated demyelinating disorders.

Hacohen and colleagues (2014) noted that auto-antibodies to glial, myelin and neuronal antigens have been reported in a range of central demyelination syndromes and autoimmune encephalopathies in children, but there has not been a systematic evaluation across the range of CNS autoantibodies in childhood-acquired demyelinating syndromes (ADS). Children under the age of 16 years with first-episode ADS were identified from a national prospective surveillance study; serum from 65 patients had been sent for a variety of diagnostic tests. Antibodies to astrocyte, myelin and neuronal antigens were tested or re-tested in all samples. A total of 15 patients (23 %) were positive for at least 1 antibody (Ab): AQP4-Ab was detected in 3 (2 presenting with NMO and 1 with isolated ON); MOG-Ab was detected in 7 (2 with ADEM, 2 with ON, 1 with TM and 2 with clinically isolated syndrome [CIS]). N-Methyl-D-Aspartate receptor (NMDAR)-Ab was found in 2 (1 presenting with ADEM and 1 with ON). Voltage-gated potassium channel (VGKC)-complex antibodies were positive in 3 (1 presenting with ADEM, 1 with ON and 1 with CIS). Glycine receptor antibody (GlyR-Ab) was detected in 1 patient with TM. All patients were negative for the VGKC-complex-associated proteins LGI1, CASPR2 and contactin-2. The authors concluded that a range of CNS-directed autoantibodies were found in association with childhood ADS. Moreover, they stated that although these antibodies are clinically relevant when associated with the specific neurological syndromes that have been described, further studies are needed to evaluate their roles and clinical relevance in demyelinating diseases.

Furthermore, an UpToDate review on “Differential diagnosis of acute central nervous system demyelination in children” (Lotze, 2014) states that “Differential diagnostic considerations for acute central nervous system demyelination in children include acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), optic neuritis, transverse myelitis, neuromyelitis optica (Devic disease), and various infectious, metabolic, and rheumatologic conditions. Most of these conditions are thought to be caused by immune system dysregulation triggered by an infectious agent in a genetically susceptible host. With the possible exception of the NMO-IgG autoantibody found in neuromyelitis optica, there are no disease-specific biomarkers for these conditions, making it difficult to distinguish among them at the time of the initial presentation. However, certain clinical features, laboratory results, and imaging findings can usually lead to the correct diagnosis”.

Aquaporin-4 Autoantibodies

Approximately 75 percent of patients with neuromyelitis optica (NMO) express antibodies to the aquaporin-4 (AQP4) receptor. Diagnosis of NMO requires the presence of longitudinally extensive acute myelitis (lesions extending over 3 or more vertebral segments) and optic neuritis. While absence of antibodies to the AQP4 receptor does not rule out the diagnosis of NMO, presence of this antibody is diagnostic for NMO.

Waschbisch et al (2013) stated that recurrent optic neuritis is frequently observed in multiple sclerosis (MS) and is a typical finding in NMO. Patients that lack further evidence of demyelinating disease are diagnosed with RION (recurrent isolated optic neuritis) or CRION (chronic relapsing inflammatory neuropathy) if they require immunosuppressive therapy to prevent further relapses. The etiology and disease course of this rare condition are not well-defined. These investigators studied a series of 10 patients who presented with recurrent episodes of isolated optic neuritis (ON, n = 57) and were followed over a median of 3.5 years. Visual acuity was severely reduced at the nadir of the disease (20/200 to 20/800). All patients had MRI non-diagnostic for MS/NMO and were aquaporin-4 antibody negative. Six patients fulfilled the CRION criteria. In 2 of these a single ON followed by a long disease-free interval preceded development of CRION for years, suggesting the conversion of an initially "benign" isolated ON into the chronic relapsing course. Cerebrospinal fluid (CSF) analysis revealed mild pleocytosis in 5 patients, identical oligoclonal bands in serum and CSF were observed in 2 patients, while the others remained negative. The authors concluded that recurrent ON is a disease entity that requires aggressive glucocorticoid and eventually long-term immunosuppressive therapy to prevent substantial visual impairment.

Petzold and Plant (2014) noted that CRION is an entity that was described in 2003. Early recognition of patients suffering from CRION is relevant because of the associated risk for blindness if treated inappropriately. These researchers performed a systematic literature review, irrespective of language, on CRION. They retrieved 22 case series and single reports describing 122 patients with CRION between 2003 and 2013. They reviewed the epidemiology, diagnostic work-up, differential diagnosis, and treatment (acute, intermediate, and long-term) in view of the collective data. These data suggested that CRION is a distinct nosological entity, which is sero-negative for anti-aquaporin-4 autoantibodies and recognized by and managed through its dependency on immuno-suppression.

Sakalauskaite-Juodeikiene et al (2018) stated that NMO is frequently associated with AQP4 autoantibodies (AQP4-Ab); however, studies of NMO in Lithuania are lacking. These researchers examined positivity for AQP4-Ab in patients presenting with inflammatory demyelinating CNS diseases other than typical MS in Lithuania. Data were collected from the 2 largest University hospitals in Lithuania. During the study period, there were 121 newly diagnosed typical MS cases, which were included in the MS registry database. After excluding these typical MS cases, these investigators analyzed the remaining 29 cases of other CNS inflammatory demyelinating diseases, including atypical MS (n = 14), acute transverse myelitis (TM; n = 8), acute disseminated encephalomyelitis (ADEM; n = 3), clinically isolated syndrome (CIS; n = 2), atypical optic neuritis (ON; n = 1), and NMO (n = 1). These researchers assessed positivity for AQP4-Ab for the 29 patients and evaluated clinical, laboratory, and instrumental differences between AQP4-Ab sero-positive and AQP4-Ab sero-negative patient groups. AQP4-Ab test was positive for 3 (10.3 %) patients in this study, with initial diagnoses of atypical MS (n = 2) and ADEM (n = 1); 1 patient was AQP4-Ab negative despite being previously clinically diagnosed with NMO. There were no significant clinical, laboratory, or instrumental differences between the groups of AQP4-Ab positive (3 [10.3 %]) and negative (26 [89.7 %]) patients. The authors concluded that AQP4-Ab test was positive for 1/10 of patients with CNS inflammatory demyelinating diseases other than typical MS in this study. They stated that AQP4-Ab testing is highly recommended for patients presenting with not only TM and ON but also an atypical course of MS and ADEM.

Multi-Analyte Assays with Algorithmic Analyses (MAAAs)

Multi-analyte assays with algorithmic analyses (MAAAs) are laboratory measurements that use a mathematic formula to analyze multiple markers that may be associated with a particular disease state and are designed to evaluate disease activity or an individual’s risk for disease. The laboratory performs an algorithmic analysis using the results of the assays and sometimes other individual information, such as gender and age and converts the information into a numeric score, which is conveyed on a laboratory report. Generally, MAAAs are exclusive to a single laboratory that owns the algorithm; MAAAs are suggested to assess risk, to diagnose or monitor disease activity of conditions such as epilepsy, as well as autoimmune connective tissue disease (CTD) and hepatitis C.

Autoimmune Epilepsy Evaluation uses a gene sequencing multi-analyte panel to analyze 5 antibodies purportedly associated with autoimmune epilepsy. The autoantibodies included in the test are:

contactin-associated protein-like 2 (CASPR2),
glutamic acid decarboxylase (GAD65),
leucine-rich, glioma inactivated 1 (LGI1),
NMDA Receptor (NR1), and
voltage-gated potassium channel complex (VGKC).

Antibody Tests for Screening of Neurologic Diseases

Tebo and colleagues (2016) noted that significant progress has been made in understanding the role and diversity of autoantibodies in the pathogenesis, diagnosis and management of paraneoplastic syndrome (PNS) and related autoimmune neurologic diseases. These investigators evaluated the positivity rates for diverse autoantibody panels to rationalize testing strategies and utilization. The result patterns for different autoantibody panels for PNS offered at 2 reference laboratories in the U.S. were retrospectively reviewed for the same period. The positivity rates were evaluated and compared for specific autoantibodies within panels offered at both laboratories. For the Hu, Ri, Yo, and amphiphysin antibodies offered by both laboratories, no significant difference in positivity rates was observed. The positivity rates for non-classic PNS markers were 0 % [AGNA and PCCA-Tr], and 0.06 % [ANNA-3 and PCAC-2] while the prevalence of antibodies associated with neuromuscular autoimmunity varied from 1.40 % to 4.44 % [Striated muscle, AChR binding, ganglionic AChR, VGCC, P/Q- and N-type VGCC]. The authors concluded that these data suggested that test utilization could be substantially improved based on ordering practice geared towards clinical manifestations and prevalence of autoantibodies. Moreover, they stated that concerted efforts towards streamlining diagnostic algorithms based on risk, clinical manifestations, characterization of autoantibodies and their associations as well as therapeutic strategies are needed.

Antibodies to Myelin Oligodendrocyte Glycoprotein for Diagnosis of Demyelinating Disease

Mariotto and colleagues (2019) determined the diagnostic relevance of myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) in CSF of sero-negative cases by retrospectively analyzing consecutive time-matched CSF of 80 MOG-Ab-seronegative patients with demyelinating disease. The cohort included 44 patients with neuromyelitis optica spectrum disorders (NMOSD) and related disorders and 36 patients with MS. Two independent neurologists blinded to diagnosis analyzed MOG-Abs by live cell-based immunofluorescence assay with goat anti-human immunoglobulin (Ig) G (whole molecule) antibody. Sera were tested at dilutions of 1:20 and 1:40, and a cut-off of 1:160 was considered for serum positivity. CSF specimens were tested undiluted and at 1:2 dilution with further titrations in case of positivity. Anti-IgG-Fc and anti-IgM-µ secondary antibodies were used to confirm the exclusive presence of MOG-IgG in positive cases. CSF of 13 MOG-Abs sero-positive cases and 36 patients with neurodegenerative conditions was analyzed as controls. A total of 3 sero-negative cases had CSF MOG-Abs (4 % of the whole cohort or 7 % of cases excluding patients with MS, in which MOG-Abs appeared to lack diagnostic relevance). In particular, 2 patients with neuromyelitis optica spectrum disorder (NMOSD) and 1 with acute disseminated encephalomyelitis had MOG-Abs in CSF. Analysis with anti-IgG-Fc and anti-IgM confirmed the exclusive presence of MOG-IgG in the CSF of these patients. Among the control group, MOG-Abs were detectable in the CSF of 8 of 13 MOG-Ab-sero-positive cases and in none of the patients with neurodegenerative disorders. The authors concluded that although serum is the optimal specimen for MOG-Ab testing, analyzing CSF could improve diagnostic sensitivity in sero-negative patients. These researchers stated that this observation has relevant diagnostic impact and might provide novel insight into the biological mechanisms of MOG-Ab synthesis. These findings suggested that CSF testing could be useful in patients with negative serum MOG-Abs if the clinical features are highly suggestive. These researchers stated that larger systematic studies are needed to determine the relevance of restricted CSF MOG-Abs and whether MOG-specific CSF antibodies reflects a distinct phenotype.

In an editorial that accompanied the afore-mentioned study, Waters and Vincent (2019) noted that “The findings in this report raise questions. Would the results have been the same if patients were tested earlier in the disease course? Could there be a different etiologic basis for CSF-positive/serum-negative patients? Other aspects of MOG-IgG-associated disease require answers, some of which are now priorities. For how long do we treat MOG-IgG-positive patients? Do we treat children in a fashion similar to the way we treat adults? How can we predict relapsing patients? Currently, we capture relapsing patients but cannot predict relapses; perhaps CSF evaluation at first episode will take us a step closer. Further prospective studies in pediatric and adult cohorts are a priority”.

Anti-HH3 and Ns6S Antibody Testing for Amyotrophic Lateral Sclerosis (ALS)-Motor Neuron Disease

Pestronk et al (2010) noted that serum IgM binding to GM1 ganglioside (GM1) is often associated with chronic acquired motor neuropathies. These researchers compared the frequency and clinical associations of serum IgM binding to a different antigen, a disulphated heparin disaccharide (NS6S), with results of IgM binding to GM1. Serums and clinical features were retrospectively compared from 75 patients with motor neuropathies and 134 controls with amyotrophic lateral sclerosis (ALS), chronic immune demyelinating polyneuropathy (CIDP) and sensory neuropathies. Clinical correlations of positive IgM anti-GM1 testing found in 27 of 2,113 unselected serums were also reviewed. Serum testing for IgM binding to NS6S and GM1 used covalent antigen linkage to ELISA plates. High-titer IgM binding to NS6S and GM1 each occurred in 43 %, and to 1 of the 2 in 64 %, of motor neuropathy patients. Motor neuropathy syndromes were present in 25 of 27 patients with high titer serum IgM binding to GM1 in the unselected serums. IgM anti-GM1 or NS6S antibody related motor neuropathy syndromes usually have asymmetric, predominantly distal, upper extremity weakness. The authors concluded that IgM binding to NS6S disaccharide was associated with motor neuropathy syndromes and occurred with similar frequency to IgM binding to GM1. Testing for IgM binding to NS6S in addition to GM1 increased the frequency of finding IgM autoantibodies in motor neuropathies from 43 % to 64 %. High titers of serum IgM binding to GM1, tested with covalent ELISA methodology, had 93 % specificity for motor neuropathy syndromes. High titers of serum IgM binding to NS6S have specificity for immune motor neuropathies compared with ALS and CIDP.

Furthermore, an UpToDate review on “Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease” (Elman and McCluskey, 2021) does not mention anti-HH3 and Ns6S antibody testing as a management option.

Anti-Neuronal Antibodies Testing in Children with Seizures Under 3 Years of Age

In a prospective, national cohort, population-based study, Symonds and colleagues (2020) reported the prevalence of anti-neuronal antibodies in children presenting with seizures before their 3rd birthday. This trial involved all children presenting with new-onset epilepsy or complex febrile seizures before their 3rd birthday over a 3-year period. Patients with previously identified structural, metabolic, or infectious cause for seizures were excluded. Serum samples were obtained at first presentation and tested for 7 neuronal antibodies using live cell-based assays. Clinical data were collected with structured proformas at recruitment and 24 months after presentation. Furthermore, patients with seizures and clinically suspected autoimmune encephalitis were independently identified by a review of the case records of all children of less than 3 years of age in Scotland who had undergone EEG. A total of 298 patients were identified and recruited and underwent autoantibody testing. Antibody positivity was identified in 18 of 298 (6.0 %). The antibodies identified were GABA receptor B (n = 8, 2.7 %), contactin-associated protein 2 (n = 4, 1.3 %), glycine receptor (n = 3, 1.0 %), leucine-rich glioma inactivated 1 (n = 2, 0.7 %), NMDA receptor (n = 1, 0.3 %), and GABA receptor A (n = 1, 0.3 %). None of these patients had a clinical picture of autoimmune encephalitis. Seizure classification and clinical phenotype did not correlate with antibody positivity. The authors concluded that a small proportion of children presenting with seizures in the first 36 months of life have circulating neuronal antibodies. In only a very small fraction of cases were they associated with a clinical picture of autoimmune encephalitis. The significance of antibody positivity in those without encephalitis is unclear, but these were unlikely to provide an etiologic explanation for the epilepsy. These investigators did not recommend routine testing for neuronal antibodies in patients presenting with early childhood-onset epilepsy because, in the absence of other features of autoimmune encephalitis, antibody positivity is of doubtful clinical significance. Antibody testing should be reserved for patients with additional features of encephalitis.

The authors stated that this study had several drawbacks. First, the prevalence of positive neuronal antibodies in healthy young children without epilepsy is unclear. These researchers relied on published data from adult healthy controls. Second, in the majority of patients, only serum samples were tested. Testing for antibodies in the CSF may be appropriate only if lumbar puncture is clinically indicated. Third, samples were tested only at initial presentation with seizures. Repeat testing over a period of time may determine the natural course of antibody positivity. Fourth, this study included only children of less than 3 years of age, an age group not typically thought to be at high risk for autoimmune encephalitis. Fifth, in young infants, immunoglobulin G antibodies may be trans-placentally transmitted from the mother. These researchers did not test mothers in this cohort for antibodies. Sixth, this study was limited to the common neuronal antibodies and did not test for other rarer encephalitis-associated neuronal antibodies. Finally, future follow-up studies of these patients are needed to establish the natural course and the relationship between antibody positivity and later development of autoimmune neurologic syndromes.

Measurement of Serum Folate Receptor Autoantibodies (e.g., FRAT (Folate Receptor Antibody Test)) for Evaluation of Patients with Cerebral Folate Deficiency Syndrome

Cerebral folate deficiency (CFD) is a condition in which concentrations of 5-methyltetrahydrofolate (5MTHF) are low in the brain as measured in the CSF despite being normal in the blood. Symptoms typically appear at about 5 to 24 months of age. Without treatment there may be poor muscle tone, trouble with coordination, trouble talking, and seizures.

Ramaekers et al (2005) noted that in infantile-onset CFD, 5MTHF levels in the CSF are low; however, folate levels in the serum and erythrocytes are normal. These investigators examined serum specimens from 28 children with CFD, 5 of their mothers, 28 age-matched control subjects, and 41 patients with an unrelated neurologic disorder. Serum from 25 of the 28 patients and 0 of 28 control subjects contained high-affinity blocking autoantibodies against membrane-bound folate receptors that are present on the choroid plexus. Oral folinic acid normalized 5MTHF levels in the CSF and resulted in clinical improvement. The authors concluded that CFD is a disorder in which autoantibodies could prevent the transfer of folate from the plasma to the CSF.

Ramaekers and Quadros (2022) stated that CFD syndrome (CFDS) is defined as any neuropsychiatric or developmental disorder characterized by decreased CSF folate levels in the presence of normal folate status outside the nervous system. The specific clinical profile appeared to be largely determined by the presence or absence of intra-uterine folate deficiency as well as post-natal age at which cerebral folate deficiency occurs. The primary cause of CFDS is identified as the presence of serum folate receptor-alpha (FRα) autoantibodies impairing folate transport across the choroid plexus to the brain whereas, in a minority of cases, mitochondrial disorders, inborn errors of metabolism and loss of function mutations of the FRα (FOLR1) gene are identified. Early recognition and diagnosis of CFDS and prompt intervention is important to improve prognosis with successful outcomes.

Anti-KLHL11 Antibody Testing

Song et al (2023) stated that anti-Kelch-like protein 11 (KLHL11) antibody encephalitis is a rare clinical condition characterized by autoimmune-mediated encephalomyelitis associated with the presence of KLHL11 antibodies. Diagnosis requires the detection of serum and CSF anti-KLHL11 antibodies, while immunotherapy serves as the main therapeutic approach. These investigators discussed a case-report highlighting the emergence of anti-KLHL11 antibody encephalitis. This case entailed a 66-year-old man who presented with seizures, impaired cognitive function, disturbance of consciousness, apathy, hypologia, dysphoria, and ataxia. Serum and CSF were identified as positive for anti-KLHL11 antibodies, resulting in a diagnosis of autoimmune encephalitis associated with KLHL11 antibodies. After treatment with glucocorticoid, the patient did not experience further convulsions and recovered consciousness, with improved cognitive function. Tumor screening suggested the presence of an underlying malignancy. The authors concluded that KLHL11 antibody encephalitis lacks typical clinical manifestations; its diagnosis requires a combination of clinical symptoms, signs, and supplementary examinations, and relies mainly on detection of anti-KLHL11 antibodies in serum and/or CSF. These investigators stated that anti-KLHL11 antibody encephalitis should be considered in males with acute or subacute onset, progressive exacerbation, and brainstem or cerebellar damage with or without limbic lobe damage. Early recognition is essential, and immunotherapy and tumor treatment can prevent neurological dysfunction and improve prognosis.

An UpToDate review on “Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis” (Dalmau and Rosenfeld, 2024) states that “ Antibodies to Kelch-like protein 11 (KLHL11) have been described in patients with a predominant brainstem/cerebellar encephalitis, often with sensorineural hearing loss, and are often but not invariably associated with tumors, most commonly benign teratoma or a testicular tumor. Other symptoms may include limbic encephalitis, myelitis, hypersomnia, and seizures. Both males and females can be affected, and patients ranging in age from 9 to 76 years have been reported. These antibodies have also been described in patients with other types of autoimmune encephalitis, including anti-N-methyl-D-aspartate (NMDA) receptor and anti-Ma2 encephalitis. In these patients, the presence of KLHL11 antibodies did not confer distinct clinical features”.

RNA Polymerase III Antibody Testing for Diagnosis and Prognostication of Scleroderma (Systemic Sclerosis)

Wielosz et al (2020) stated that anti-RNA polymerase III (a-RNA Pol III) antibodies are marker antibodies in patients with systemic sclerosis (SSc). These investigators examined the prevalence of a-RNA Pol III in patients with SSc and identified the differences in the disease picture in SSc patients with and without a-RNA Pol III antibodies. The study was carried out in 126 SSc patients. The subtype of SSc, incidence of internal organ involvement, malignancy, death, and serological profiles were determined in the entire group. The study groups were studied according to the presence of antibodies by applying the commercial test -- EUROLINE SSc Profile. Due to the presence of a-RNA Pol III, patients were divided into 2 groups: the a-RNA Pol III (+) SSc group of 19 patients, and the a-RNA Pol III (–) SSc group of 107 patients. A-RNA Pol III were present in 19/126 patients with SSc (15 %), 13/19 (68.4 %) patients had no other SSc marker antibodies. A-RNA Pol III were more common in patients with diffuse cutaneous SSc (p = 0.049). These researchers showed a significant positive association between a-RNA Pol III and occurrence of malignancy (p = 0.007), scleroderma renal crisis (p = 0.001), and decreased diffusing capacity of the lung for carbon monoxide (DLCO) (p = 0.007). The authors concluded that anti-a-RNA Pol III antibodies were common in patients with SSc, especially with a diffuse subtype. In more than 50 % of patients with a-RNA Pol III antibodies, they may be present as the sole marker of antibodies. In SSc, a-RNA Pol III antibodies are often associated with malignancy occurrence, kidney and lung involvement.

These investigators stated that according to these findings, a-RNA Pol III antibodies are quite common in patients with SSc, particularly with a diffuse subtype. In more than 60 % of patients a-RNA Pol III antibodies may be present as the sole marker of SSc antibodies. In SSc a-RNA Pol III antibodies are often associated with malignancy occurrence and development of scleroderma renal crisis. To sum up, measurements of a-RNA Pol III antibodies are useful in routine clinical practice because they are one of the marker antibodies in SSc diagnosis, and in many cases they identify the subset of the disease with severe skin and renal involvement. In addition, the presence of a-RNA Pol III antibodies should alert physicians to an increased risk of scleroderma renal crisis and monitoring of blood pressure (BP) for early detection of this complication since the prompt introduction of angiotensin-converting enzyme (ACE) inhibitor can be life-saving. Moreover, the presence of a-RNA Pol III antibodies in SSc patients requires screening for associated cancer, even in the absence of clinical signs.

Junior et al (2022) conducted a systematic review of the clinical manifestations and complementary examinations of patients with myopathies and SSc overlap syndrome (MyoSScOS). Systematic review from January 1976 to November 2021 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement on 3 electronic databases: PubMed, Web of Science, and Scopus. Studies were analyzed based on the following eligibility criteria: at least 1 combination of the terms described in the search strategy appeared in the title; written in English, Portuguese, or Spanish; and addresses MyoSScOS. Brief communications, reviews, studies that addressed myopathies in children, congress proceedings, monographs, and dissertations were excluded. A total of 35 studies were selected. MyoSScOS appeared to be more common in women. It also often affects the esophagus and joints with symmetrical and bilateral muscle involvement, Raynaud's phenomenon, and impairment of forced vital capacity. Concerning SSc, the most common subtype was the diffuse form. Cardiovascular and pulmonary complications are an important cause of death. Anti-centromere, anti-PM/Scl, anti-Scl70, anti-RNA polymerase III, anti-Ku, and anti-RNP were more correlated with this entity; EMG patterns were quite similar to those found in inflammatory myopathies.

Almaabdi et al (2023) noted that SSC is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. These investigators stated that anti-topoisomerase I, anti-centromere, and anti-RNA polymerase III antibodies were deemed vitally important in the concept of SSc due to their ability to distinguish SSc from other systemic autoimmune rheumatic diseases (SARD), such that they were included in the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for SSc.

Furthermore, an UpToDate review on “Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults“ (Varga, 2024) states that “Anti-RNA polymerase III antibody. Antibodies to RNA polymerase III are found in patients with dcSSc and are generally associated with rapidly progressive skin involvement as well as an increased risk for scleroderma renal crisis (SRC). These patients may also be at increased risk for concomitant cancer”.

Serum MOG-IgG Antibody Testing for Evaluation of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Chen and Bhatti (2020) reviewed the clinical characteristics, radiological manifestations and treatment of myelin oligodendrocyte glycoprotein (MOG)-immunoglobulin G (IgG) optic neuritis (ON). These investigators noted that serum antibodies to MOG have recently been found to be a biomarker of MOG-IgG-associated disorder (MOGAD), a demyelinating disease distinct from both MS and aquaporin-4-IgG NMOSD (AQP4-IgG-positive NMOSD). The phenotype of MOGAD is broad and includes ON, TM, and ADEM. Optic neuritis is the most common presentation in adults, whereas ADEM is the most common presentation in children. Clinical characteristics suggestive of MOG-IgG ON include recurrent ON, prominent disc edema, and perineural enhancement of the optic nerve on MRI. Although the nadir of vision loss is severe with MOG-IgG ON, the recovery is typically better than AQP4-IgG ON and thus has a favorable overall prognosis. Patients with relapsing disease will often need chronic immunotherapy. Rituximab, azathioprine, mycophenolate mofetil, and monthly intravenous immune globulin (IVIG) are the most commonly used treatments. The authors concluded that MOGAD is a unique entity that is separate from both MS and AQP4-IgG-positive NMOSD. These investigators stated that recognition of the clinical and radiologic features allowed for the correct diagnosis.

Wendel et al (2022) stated that the spectrum of MOGAD comprises monophasic diseases such as ADEM, ON, and TM, as well as relapsing courses of these presentations. Persistently high MOG antibodies (MOG immunoglobulin G [IgG]) are found in patients with a relapsing disease course. Prognostic factors to determine the clinical course of children with a 1st MOGAD are still lacking. In a prospective, hospital-based, multi-center study, these researchers examined the clinical and laboratory prognostic parameters for a risk of relapse and the temporal dynamics of MOG-IgG titers in children with MOGAD in correlation with clinical presentation and disease course. This trial included children with a 1st demyelinating attack and complete data set comprising clinical and radiologic findings, MOG-IgG titer at onset, and clinical and serologic follow-up data. Serum samples were analyzed by live cell-based assay, and a titer level of 1:160 or higher was classified as MOG-IgG-positive. A total of 116 children (female/male = 57/59) with MOGAD were included, and initially diagnosed with ADEM (n = 59), unilateral ON (n = 12), bilateral ON (n = 16), myelitis (n = 6), NMOSD (n = 8) or encephalitis (n = 6). The median follow-up time was 3 years in monophasic, and 5 years in relapsing patients. There was no significant association between disease course and MOG-IgG titers at onset, sex, age at presentation, or clinical phenotype. Sero-conversion to MOG-IgG-negative within 2 years of the initial event showed a significant risk reduction for a relapsing disease course. 42/116 patients (monophasic n = 26, relapsing n = 16) had serial MOG-IgG testing in years 1 and 2 after the initial event. In contrast to relapsing patients, monophasic patients showed a significant decrease of MOG-IgG titers during the 1st and 2nd years, often with sero-conversion to negative titers. During the follow-up, MOG-IgG titers were persistently higher in relapsing than in monophasic patients. Decrease in MOG-IgG of 3 or higher dilution steps after the 1st and 2nd years was shown to be associated with a decreased risk of relapses. In this cohort, no patient experienced a relapse after sero-conversion to MOG-IgG-negative. The authors concluded that in this study, patients with declining MOG-IgG titers, especially those with sero-conversion to MOG-IgG-negative, are shown to have a significantly reduced relapse risk.

Xu et al (2023) stated that MOGAD has gained recognition in recent years as an immune-mediated inflammatory demyelinating disease of the CNS. The clinical features and prognosis of MOGAD adult cerebral cortical encephalitis (adult CCE) have not been fully elucidated. These investigators characterized the clinical symptoms, MRI findings, and prognosis of CCE with anti-MOG antibody. They presented 2 adult cases of CCE with anti-MOG antibody and summarized the clinical symptoms, MRI findings, and prognosis of this phenotype via a completed systematic review of the literature. These researchers found a total of 39 cases of MOGAD adult CCE (36 % women; average age of onset of 29 years). Among them, 85 % had seizure, 82 % had headache, 64 % had cortical symptoms, 64 % had fever, 54 % had changes of consciousness, and 38 % had ocular symptoms. All cases showed cerebral cortical T2 fluid-attenuated inversion recovery (FLAIR) lesions on MRI. Of the 25 patients (with seizure or not) who had EEG reports, 76 % of patients showed abnormal EEG; CSF white blood cell count of 90 % of patients and CSF total protein of 67 % of patients were elevated. In 16 patients with available CSF cytology data, 11 (69 %) had abnormal cytology findings with monocytic predominance. In the 15 cases for which MOG antibody IgG was tested in both serum and CSF, 14 (93 %) revealed a higher positive MOG IgG titer in serum than CSF. The majority of patients were treated with immunosuppressive therapy (97 % corticosteroids, 15 % mycophenolate mofetil, 13 % IVIG, 5 % azathioprine, and 5 % other). The majority of patients had a favorable prognosis following treatment, as indexed by improved clinical symptoms and imaging; 2 patients relapsed. The authors concluded that the clinical presentation and prognosis of adult CCE remain less understood in comparison to more common MOGAD phenotypes. These investigators noted that it is important to consider MOGAD as an underlying etiology for adult CCE, as early detection and immunotherapy may improve outcomes.

Banwell et al (2023) noted that serum antibodies directed against MOG are found in patients with acquired CNS demyelinating syndromes that are distinct from MS and AQP4-IgG-positive NMOSD. Based on an extensive literature review and a structured consensus process, these investigators proposed diagnostic criteria for MOGAD in which the presence of MOG-IgG is a core criterion. According to the proposed criteria, MOGAD is typically associated with ADEM, ON, or TM, and is less commonly associated with CCE, brainstem presentations, or cerebellar presentations. MOGAD can present as either a monophasic or relapsing disease course, and MOG-IgG cell-based assays are important for diagnostic accuracy. Diagnoses such as MS need to be excluded, but not all patients with MS should undergo screening for MOG-IgG.

Furthermore, an UpToDate review on “Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis” (Flanagan and Tillema, 2024) states that “Clinical presentations that should raise suspicion for MOGAD include the following:

Optic neuritis that is simultaneously bilateral, involves the anterior optic pathway, and is associated with optic disc edema.
Acute disseminated encephalomyelitis (ADEM) or ADEM-like presentations accompanied by large, poorly demarcated T2 hyperintense lesions in the brain and with T2 lesions within the spinal cord.
Unilateral cortical encephalitis with headache, fever, seizures, encephalopathy, or other focal neurologic findings with cortical T2 hyperintensity and swelling.
A complete (rather than partial) spinal cord syndrome, especially with prominent bowel, bladder, or erectile dysfunction symptoms.

We test for serum MOG-IgG antibody using a cell-based assay. Testing is indicated for patients with characteristic clinical, MRI, and laboratory features of MOGAD and in those with a CNS demyelinating syndrome that is atypical for MS. Clinical judgement is required when selecting patients for MOG-IgG testing and when interpreting a positive result, since false positives results do occur. Uniform testing of MOG-IgG for patients who present with clinical features and have MRI findings typical for MS is not recommended”.

Appendix

Table 1: Disorders Associated with Antibodies to Glycolipid and Glycoprotein-Related Saccharides
Neuropathy Syndrome	Antibody Target	Antibody Isotype
Chronic Sensory-Motor Demyelinating	Myelin-associated glycoprotein (MAG) Other: SGPG	IgM (monoclonal)
Chronic ataxic neuropathy	GD1b, GQ1b	IgM (monoclonal)
Motor neuropathy	GM1	IgM (polyclonal or monoclonal)
Sensory neuropathy	Sulfatide	IgM (monoclonal or polyclonal)
Acute motor axonal neuropathy	GM1, GD1a	IgG
Miller Fisher syndrome Bickerstaff's brainstem encephalitis Acute ophthalmoparesis Ataxic Guillain-Barré syndrome	GQ1b, GT1a	IgG
Pharyngeal-cervical-brachial weakness	GT1a (GQ1b)	IgG

Adapted from: Pestronk, 2008.

Table 2: Antibodies Associated with Paraneoplastic Syndromes and Associated Cancers
Antibody	Syndrome	Associated Cancers
Well characterized paraneoplastic antibodiesFootnotes for well characterized paraneoplastic antibodies*
Anti-Hu (ANNA-1)	Paraneoplastic encephalomyelitis including cortical, limbic, brainstem encephalitis; paraneoplastic cerebellar degeneration, myelitis; paraneoplatic sensory neuronopathy, and/or autonomic dysfunction	SCLC, other
Anti-Yo (APCA-1)	Paraneoplastic cerebellar degeneration	Gynecological, breast
Anti-Ri (ANNA-2)	Paraneoplastic cerebellar degeneration, brainstem encephalitis, opsoclonus-myoclonus	Breast, gynecological, SCLC, Hodgkin's lymphoma
Anti-Tr	Paraneoplastic cerebellar degeneration	SCLC, thymoma, other
Anti-CV2/CRMP5	Paraneoplastic encephalomyelitis, paraneoplastic cerebellar degeneration, chorea, peripheral neuropathy	Germ-cell tumors of testis, lung cancer, other solid tumors
Anti-Ma proteins (Ma1, Ma2)Footnotes for Anti-Ma proteins (Ma1, Ma2) ***	Limbic, hypothalamic, brainstem encephalitis (infrequently paraneoplastic cerebellar degeneration)	Breast, testicular, other
Anti-amphiphysin	Stiff-person syndrome, paraneoplastic encephalomyelitis	SCLC
Anti-recoverin	Cancer-associated retinopathy (CAR)
Partially-characterized paraneoplastic antibodiesFootnotes for Partially-characterized paraneoplastic antibodies**
Anti-Zic 4	Paraneoplastic cerebellar degeneration	SCLC
mGluR1	Paraneoplastic cerebellar degeneration	Hodgkin's lymphoma
ANNA-3	Paraneoplastic sensory neuronopathy, paraneoplastic encephalomyelitis	SCLC
PCA2	Paraneoplastic encephalomyelitis, paraneoplastic cerebellar degeneration	SCLC
Anti-bipolar cells of the retina	Melanoma-associated retinopathy (MAR)	Melanoma
Antibodies that occur with and without cancer association
Anti-VGCC	Lambert-Eaton myasthenic syndrome, paraneoplastic cerebellar dysfunction	SCLC
Anti-AChR	Myasthenia gravis	Thymoma
Anti-VGKC	Neuromyotonia, limbic encephalitis, seizures	Thymoma, others
nAChR	Subacute pandysautonomia	SCLC, others

Key: AChR: acetylcholine receptor; APCA: anti-Purkinje cell antibody; ANNA: anti-neuronal-nuclear antibody; SCLC: small-cell lung cancer; VGCC: voltage-gated calcium channel; VGKC: voltage-gated potassium channel; nAChR: ganglionic nicotinic acetylcholine receptor antibodies.

Footnotes for well characterized paraneoplastic antibodies*Well-characterized antibodies are those directed against antigens whose molecular identity is known, or that have been identified by several investigators.

Footnotes for Partially-characterized paraneoplastic antibodies**Partially-characterized antibodies are those whose target antigens are unknown or require further analysis in groups of individuals serving as controls.

Footnotes for Anti-Ma proteins (Ma1, Ma2) ***Antibodies to Ma2: younger than 45 years, usually men with testicular germ-cell tumors; older than 45, men or women with lung cancer and less frequently other tumors. Ma1 antibodies often associated with tumors other than germ-cell neoplasms and confers a worse prognosis, with more prominent brainstem and cerebellar dysfunction.

Adapted from: Dalmau and Rosenfeld, 2006; Bataller and Dalmau, 2004.

References

The above policy is based on the following references:

Aguirre-Cruz L, Charuel JL, Carpentier AF, Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases. J Neurooncol. 2005;71(1):39-41.
Almaabdi K, Ahmad Z, Johnson SR. Advanced autoantibody testing in systemic sclerosis. Diagnostics (Basel). 2023;13(5):851.
Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.
Bataller L, Dalmau JO. Paraneoplastic disorders of the central nervous system: Update on diagnostic criteria and treatment. Semin Neurol. 2004;24(4):461-471.
Bataller L, Kleopa KA, Wu GF, et al. Autoimmune limbic encephalitis in 39 patients: Immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78(4):381-385.
Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology. 2004;62(5):778-782.
Baumann N, Harpin ML, Marie Y, et al. Antiglycolipid antibodies in motor neuropathies. Ann N Y Acad Sci. 1998;854:322-329.
Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features. Neurology. 2010;75(22):1961-1967.
Chan AY, Liu DT. Bread-and-butter in diagnosis of myasthenia gravis. Arch Neurol. 2005;62(6):1002-1003.
Chang I. Diagnosis of peripheral neuropathies. CNI review library. Colorado Neurological Institue. Englewood, CO:2002;13(2). Available at: http://www.thecni.org/reviews/13-2-p11-chang.htmAccessed May 7, 2008.
Chang T, Lang B. GAD antibodies in stiff-person syndrome. Neurology. 2004;63(11):1999-2000.
Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47-54.
Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66(10):1345-1349.
Conrad K, Schneider H, Ziemssen T, et al. A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. Ann N Y Acad Sci. 2007;1109:256-264.
Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology. Brain Pathol. 1999;9(2):275-284.
Dalmau J, Rosenfeld M. Paraneoplastic syndromes affecting peripheral nerve and muscle. UpToDate [serial online]. Waltham, MA: UpToDate; reviewed September 2006.
Dalmau J, Rosenfeld MR. Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis. UpToDate [online serial}. Waltham, MA: UpToDate; reviewed January 2024.
Derfuss T, Meinl E. Identifying autoantigens in demyelinating diseases: Valuable clues to diagnosis and treatment? Curr Opin Neurol. 2012;25(3):231-238.
Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991;325(21):1482-1486.
Elman LB, McCluskey L. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed January 2021.
Eurelings M, Moons KG, Notermans NC, et al. Neuropathy and IgM M-proteins: Prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology. 2001;56(2):228-233.
Finsterer J, Muellbacher W, Halbmayer WM, et al. Anti-GM1 antibodies in polyneuropathies of unknown origin. J Clin Pathol. 1996;49(5):422-425.
Flanagan EP, Tillema J-M. oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed February 2024.
Fluri F, Ferracin F, Erne B, Steck AJ. Microheterogeneity of anti-myelin-associated glycoprotein antibodies. J Neurol Sci. 2003;207(1-2):43-49.
Garces-Sanchez M, Dyck PJ, Kyle RA, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008;37(4):490-495.
Goroll AH. Primary Care Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:952.
Griffin JW, Hsieh ST, McArthur JC, et al. Laboratory testing in peripheral nerve disease. Neurol Clin. 1996;14(1):119-133.
Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123 ( Pt 7):1481-1494.
Hacohen Y, Absoud M, Woodhall M, et al; On behalf of UK & Ireland Childhood CNS Inflammatory Demyelination Working Group. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: Results from a national surveillance cohort. J Neurol Neurosurg Psychiatry. 2014;85(4):456-461.
Hayes KC, Hull TC, Delaney GA, et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma. 2002;19(6):753-761.
Hughes RA. Peripheral neuropathy. BMJ. 2002;324(7335):466-469.
Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Soc. J Peripher Nerv Syst. 2006;11(1):9-19.
Junior JG, Mugii N, Inaoka PT, et al. Inflammatory myopathies overlapping with systemic sclerosis: A systematic review. Clin Rheumatol. 2022;41(7):1951-1963.
Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135(6):1550-1556.
Lancaster E. Paraneoplastic disorders. Continuum (Minneap Minn). 2017;23(6, Neuro-oncology):1653-1679.
Latov N, Sferruzza A. Laboratory diagnosis of peripheral neuropathy. Clinical Application Paper. Madison, NJ: Quest Diagnostics; updated November 2007. Available at: http://www.questdiagnostics.com/hcp/intguide/jsp/showintguidepage.jsp?fn=CAP_LabDiagnosis_PeripheralNeurop.htm. Accessed December 3, 2008.
Lee JY, Sung JJ, Cho JY, et al. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci. 2006;13(3):353-355.
Liebeskind DS. Paraneoplastic encephalomyelitis. eMedicine Neurology Topic 300. Omaha, NE: eMedicine.com; updated November 2, 2005. Available at: http://www.emedicine.com/neuro/topic300.htm. Accessed January 31, 2006.
Lopez PH, Comín R, Villa AM, et al. A new type of anti-ganglioside antibodies present in neurological patients. Biochim Biophys Acta. 2006;1762(3):357-361.
Lotze TE. Differential diagnosis of acute central nervous system demyelination in children. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed January 2014.
Low PA, Stevens C, Suarez GA, et al. Diseases of peripheral nerves. In: Clinical Neurology. RJ Joynt, RC Griggs, eds, Philadelphia, PA: Lippincott-Raven; 1996;4(51):91-92.
Lucchinett CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50(3):652-657.
Maisonobe T, Chassande B, Verin M, et al. Chronic dysimmune demyelinating polyneuropathy: A clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry. 1996;61(1):36-42.
Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol. 2004;24(2):149-53.
Mariotto S, Gajofatto A, Batzu L, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology. 2019;93(20):e1867-e1872.
Mehdi A, Ko DY. Paraneoplastic cerebellar degeneration. eMedicine Neurology Topic 299. Omaha, NE: eMedicine.com; updated January 30, 2002. Available at: http://www.emedicine.com/neuro/topic299.htm. Accessed October 17, 2002.
Miller ML. Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis. UpToDate [online serial]. Waltham, MA: UpToDate; September 2009.
Murinson BB, Butler M, Marfurt K, et al. Markedly elevated GAD antibodies in SPS: Effects of age and illness duration. Neurology. 2004;63(11):2146-2148.
O'Ferrall EK, White CM, Zochodne DW. Demyelinating symmetric motor polyneuropathy with high titers of anti-GM1 antibodies. Muscle Nerve. 2010;42(4):604-608.
Pappu R, Seetharaman M. Polymyositis: Differential diagnoses & workup. Omaha, NE: eMedicine.com; updated November 6, 2009. Available at: http://emedicine.medscape.com/article/335925-diagnosis. Accessed March 15, 2010.
Pearce DA, Atkinson M, Tagle DA. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology. 2004;63(11):2001-2005.
Pestronk A. Treatable gait disorder and polyneuropathy associated with high serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle and Nerve. 1994;17:1293-1300.
Pestronk A. Washington University. Neuromuscular Disease Center [website]. St. Louis, MO; Washington University; 2008. Available at: http://www.neuro.wustl.edu/NEUROMUSCULAR/index.html. Accessed April 24, 2008.
Pestronk A, Chuquilin M, Choksi R. Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry. 2010;81(7):726-730.
Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: A systematic review of 122 cases reported. J Neurol. 2014;261(1):17-26.
Pourmand R. Autoantibody testing. Neurol Clin. 2004;22(3):703-717, vii.
Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol. 2002;27(5):384-387.
Ramaekers VT, Quadros EV. Cerebral folate deficiency syndrome: Early diagnosis, intervention and treatment strategies. Nutrients. 2022;14(15):3096.
Ramaekers VT, Rothenberg SP, Sequeira JM, et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med. 2005;352(19):1985-1991.
Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455-461.
Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: Disease severity and prognosis. Eur J Neurol. 2005;12(6):413-418.
Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med. 1998;338(22):1601-1607.
Sakalauskaite-Juodeikiene E, Armaliene G, Kizlaitiene R, et al. Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. Brain Behav. 2018;8(11):e01129.
Santacroce L, Gagliardi S, Latorre V, et al. Paraneoplastic syndromes. eMedicine Neurology. Topic 1747. Omaha, NE: eMedicine.com; July 3, 2002. Available at: http://www.emedicine.com/med/topic1747.htm. Accessed October 17, 2002.
Scofield RH. Autoantibodies as predictors of disease. Lancet. 2004;363(9420):1544-1546.
Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology. 2004;62(11):1945-1950.
Senties-Madrid H, Vega-Boada F. Paraneoplastic syndromes associated with anti-Hu antibodies. Israel Med Assoc J. 2001;3:94-103.
Song Y, Hu Q, Zhang Q. Anti-Kelch-like protein 11 antibody encephalitis: A case report and literature review. Front Neurol. 2023:14:1273051.
Spiro SG, Gould MK, Colice GL; American College of Chest Physicians. Initial evaluation of the patient with lung cancer: Symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines 2nd edition). Chest. 2007;132(3 Suppl):149S-160S.
Sridharan R, Lorenzo N. Focal muscular atrophies. eMedicine Neurology Topic 137. Omaha, NE: eMedicine.com; updated July 17, 2001. Available at: http://www.emedicine.com/neuro/topic137.htm. Accessed October 17, 2002.
Steck AJ, Erne B, Gabriel JM, et al. Paraproteinaemic neuropathies. Brain Pathol. 1999;9(2):361-368.
Symonds JD, Moloney TC, Lang B, et al. Neuronal antibody prevalence in children with seizures under 3 years: A prospective national cohort. Neurology. 2020;95(11):e1590-e1598.
Tagawa Y, Yuki N, Ohnishi A, et al. Parameters for monitoring treatment effects in CIDP with anti-MAG/SGPG IgM antibody. Muscle Nerve. 2001;24(5):701-704.
Taylor BV, Gross L, Windebank AJ. The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 1996;47(4):951-955.
Tebo AE, Haven TR, Jackson BR. Autoantibody diversity in paraneoplastic syndromes and related disorders: The need for a more guided screening approach. Clin Chim Acta. 2016;459:162-169.
Tidy C. Plasma autoantibodies disease associations. Patient UK. Leeds, UK: Egton Medical Information Systems (EMIS); updated January 10, 2007. Available at: http://www.patient.co.uk/showdoc/40001200. Accessed November 11, 2008.
Tobin WO, Pittock SJ. Autoimmune neurology of the central nervous system. Continuum (Minneap Minn). 2017;23(3, Neurology of Systemic Disease):627-653.
Toro J, Cuellar-Giraldo D, Duque A, et al. Seronegative paraneoplastic limbic encephalitis associated with thymoma. Cogn Behav Neurol. 2017;30(3):125-128.
Varga J. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed January 2024.
Vedeler CA, Antoine JC, Giometto B, et al.; Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: Report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682-690.
Vincent A, Leite MI. Neuromuscular junction autoimmune disease: Muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol. 2005;18(5):519-525.
Waschbisch A, Atiya M, Schaub C, et al. Aquaporin-4 antibody negative recurrent isolated optic neuritis: Clinical evidence for disease heterogeneity. J Neurol Sci. 2013;331(1-2):72-75.
Waters P, Vincent A. Myelin oligodendrocyte glycoprotein CSF testing needs testing. Neurology. 2019;93(20):871-872.
Wendel EM, Thonke HS, Bertolini A, et al; BIOMARKER Study Group. Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome. Neurol Neuroimmunol Neuroinflamm. 2022;9(6):e200035.
Wielosz E, Dryglewska M, Majdan M. Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis. Postepy Dermatol Alergol. 2020;37(6):909-914.
Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125(Pt 12):2591-1625.
Wills AJ, Turner B, Lock RJ, et al. Dermatitis herpetiformis and neurological dysfunction. J Neurol Neurosurg Psychiatry. 2002;72(2):259-261.
Wolfe GI, Nations SP. Guide to antibody testing in peripheral neuropathies. Neurologist. 2001;7(4):195-207.
Xu M, Ma C, Dong M, et al. Two case reports and a systematic review of the literature on adult cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody. Front Immunol. 2023;14:1203615.
Zvartau-Hind M, Lewis R. Chronic inflammatory demyelinating polyneuropathy. eMedicine Neurology Topic 467. Omaha, NE: eMedicine.com; updated April 22, 2002. Available at: http://www.emedicine.com/neuro/topic467.htm. Accessed October 17, 2002.

Last Review 06/12/2024

Effective: 08/03/1999

Next Review: 04/10/2025
Review History
Definitions

Antibody Tests for Neurologic Diseases

Table Of Contents

Policy

Scope of Policy

Medical Necessity

Experimental, Investigational, or Unproven

Related Policies

CPT Codes / HCPCS Codes / ICD-10 Codes

CPT codes covered if selection criteria are met:

Measurement of CSF myelin oligodendrocyte glycoprotein antibodies - no specific code:

CPT codes not covered for indications listed in the CPB (not all-inclusive):

Other CPT codes related to the CPB:

ICD-10 codes covered if selection criteria are met:

ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):